BR112018017334A2 - comprimido de camada tripla com liberação controlada contendo pregabalina - Google Patents

comprimido de camada tripla com liberação controlada contendo pregabalina

Info

Publication number
BR112018017334A2
BR112018017334A2 BR112018017334-7A BR112018017334A BR112018017334A2 BR 112018017334 A2 BR112018017334 A2 BR 112018017334A2 BR 112018017334 A BR112018017334 A BR 112018017334A BR 112018017334 A2 BR112018017334 A2 BR 112018017334A2
Authority
BR
Brazil
Prior art keywords
tablet containing
layer tablet
triple layer
controlled release
containing pregabalin
Prior art date
Application number
BR112018017334-7A
Other languages
English (en)
Inventor
Hun Kim Kyung
Soo Lee Kyung
Heon Song Woo
Sang Park Jun
Original Assignee
Gl Pharmtech Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gl Pharmtech Corp. filed Critical Gl Pharmtech Corp.
Publication of BR112018017334A2 publication Critical patent/BR112018017334A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

é revelado um comprimido de camada tripla altamente dilatável de liberação oral controlada contendo pregabalina adequado para administração uma vez por dia.
BR112018017334-7A 2017-02-01 2017-03-29 comprimido de camada tripla com liberação controlada contendo pregabalina BR112018017334A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2017-0014586 2017-02-01
KR1020170014586A KR102039344B1 (ko) 2017-02-01 2017-02-01 프레가발린 함유 경구용 서방성 삼중정제
PCT/KR2017/003377 WO2018143511A1 (ko) 2017-02-01 2017-03-29 프레가발린 함유 경구용 서방성 삼중정제

Publications (1)

Publication Number Publication Date
BR112018017334A2 true BR112018017334A2 (pt) 2018-12-26

Family

ID=63040723

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018017334-7A BR112018017334A2 (pt) 2017-02-01 2017-03-29 comprimido de camada tripla com liberação controlada contendo pregabalina

Country Status (8)

Country Link
US (1) US10632077B2 (pt)
EP (1) EP3375438A4 (pt)
JP (1) JP6636532B2 (pt)
KR (1) KR102039344B1 (pt)
CN (1) CN108697651A (pt)
BR (1) BR112018017334A2 (pt)
EA (1) EA201891886A1 (pt)
WO (1) WO2018143511A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019238068A1 (zh) * 2018-06-13 2019-12-19 北京泰德制药股份有限公司 一种普瑞巴林缓释组合物及其制备方法
CN112245404A (zh) * 2020-11-02 2021-01-22 成都晶富医药科技有限公司 一种普瑞巴林胶囊及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
NZ332762A (en) 1996-07-24 2000-09-29 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
US7611728B2 (en) * 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
KR100885029B1 (ko) * 2007-02-07 2009-02-23 지엘팜텍 주식회사 경구투여용 서방성 삼중정제
JP2011504491A (ja) * 2007-11-23 2011-02-10 ルピン・リミテッド プレガバリンの制御放出医薬組成物
EP2440190A1 (en) * 2009-06-12 2012-04-18 Micro Labs Limited Novel pharmaceutical compositions containing pregabalin
KR101317592B1 (ko) * 2009-10-28 2013-10-15 씨제이제일제당 (주) 프레가발린, 폴리에틸렌옥사이드 및 폴리비닐알코올-폴리에틸렌글리콜 그라프트 공중합체를 함유하는 위체류형 서방성 제제
EP2575798B1 (en) * 2010-06-01 2017-08-09 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
EP2415460A1 (de) * 2010-08-03 2012-02-08 ratiopharm GmbH Orale Darreichungsform von Pregabalin
US20140161880A1 (en) 2011-07-26 2014-06-12 Yuhan Corporation Sustained release tablet comprising pregabalin through two-phase release-controlling system
KR101438546B1 (ko) * 2011-08-26 2014-09-17 근화제약주식회사 프레가발린을 포함하는 서방성 제제
ITMI20121263A1 (it) * 2012-07-19 2014-01-20 Recordati Ind Chimica E Farma Ceutica S P A Forma farmaceutica multistrato
KR20130121717A (ko) * 2013-04-16 2013-11-06 씨제이제일제당 (주) 위체류 약물전달 시스템을 이용한 서방성 제제

Also Published As

Publication number Publication date
EP3375438A4 (en) 2020-03-04
JP2019507101A (ja) 2019-03-14
WO2018143511A1 (ko) 2018-08-09
EA201891886A1 (ru) 2019-12-30
CN108697651A (zh) 2018-10-23
EP3375438A1 (en) 2018-09-19
KR20180089807A (ko) 2018-08-09
JP6636532B2 (ja) 2020-01-29
KR102039344B1 (ko) 2019-11-01
US10632077B2 (en) 2020-04-28
US20190099376A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
EP4349406A3 (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole for use as a medicament
CY1122469T1 (el) Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
BR112017028140A2 (pt) formulações farmacêuticas
TWD196337S (zh) 口腔保健器具（一）
BR112018071370A2 (pt) composições farmacêuticas orais de mesalazina
BR112019003184A2 (pt) liberação local sustentada de medicamentos, incluindo antibióticos
GEP20197020B (en) Vortioxetine pyroglutamate
BR112018017334A2 (pt) comprimido de camada tripla com liberação controlada contendo pregabalina
EP3478274A4 (en) FAST-EFFECTING FILM FOR THE ADMINISTRATION OF A LOCAL ANESTHESIA IN THE MOUTH
BR112019023664A8 (pt) Forma de dosagem em pastilha
BR112018007133A2 (pt) formulação de liberação modificada de naproxeno sódico
BR112016026422A2 (pt) solução farmacêutica compreendendo dopamina para uso no tratamento da doença de parkinson
PL3880171T3 (pl) Doustny preparat farmaceutyczny zawierający ibuprofen
PL3845230T3 (pl) Kompozycja farmaceutyczna do podawania doustnego
PL3357492T3 (pl) Wielowarstwowa tabletka do podawania magnezu
BR112019024708A2 (pt) composições farmacêuticas de liberação prolongada retardada
AR100820A1 (es) Formulaciones de comprimido bi-capa de ciclofosfamida y capecitabina y administración metronómica altamente fraccionada de las mismas
EA201891885A1 (ru) Содержащая прегабалин высоконабухаемая трехслойная таблетка с замедленным высвобождением для перорального приема
UA100326U (ru) Применение натриевой соли гидрогенсульфида для потенцирования анальгетического эффекта нестероидных противовоспалительных препаратов
PH12020550456A1 (en) Alcohol-resistant oral pharmaceutical compositions of lorazepam
PH12017500346A1 (en) Film coated tablet for the treatment of acute pain
EP3682886A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AORTIC ANEURISM
UA100342U (ru) Применение натриевой соли гидрогенсульфида как средства для снижения гастротоксичности нестероидных противовоспалительных средств

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B10A Cessation: cessation confirmed